#ARCT

StockTitan

@stocktitan.net

1 week ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress {"summary":"","positive":[],"negative":[],"faq":[]}

#ARCT Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

www.stocktitan.net/news/ARCT/arcturus-thera...

StockTitan

@stocktitan.net

4 months ago

#ARCT Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

www.stocktitan.net/news/ARCT/arcturus-thera...

Stocks to Watch

@stockstowatch.bsky.social

4 months ago

Copper, silver, and gold are near all-time highs. Producer stocks are rising and that momentum will soon reach explorers.

🎥 Watch Arctic Minerals ( #STO: #ARCT ) Executive Director Peter George share why the sector’s next wave is coming: youtu.be/Dria-r-822w?...

Stocks to Watch

@stockstowatch.bsky.social

4 months ago

Arctic Minerals' ($ARCT) Strategic Copper-Gold Opportunity in Sweden YouTube video by Stocks To Watch

Arctic Minerals ( #STO: #ARCT ) has kicked off exploration at its Swan Lake copper-gold project in Norrbotten County, Sweden, a Tier 1 mining region in Europe.

🔎 Discover why Swan Lake matters and what’s next in exploration through this interview: youtu.be/Dria-r-822w?...

StockTitan

@stocktitan.net

4 months ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program Arcturus (Nasdaq: ARCT) reported interim Phase 2 results for inhaled mRNA therapy ARCT-032 in Class I cystic fibrosis patients.In a 28-day, 10 mg cohort (6 adults) the treatment was generally safe and well tolerated; one SAE occurred well after dosing that a Data Monitoring Committee found no convincing evidence of product relatedness. AI-enhanced HRCT showed mucus plug and mucus volume reductions in 4 of 6 participants (largest mucus volume drop −67.4%). A post hoc exploratory analysis showed average ppFEV1 +3.8% absolute (+5.1% relative) in 4 of 6 participants vs pre-treatment baseline. A 12-week safety and preliminary efficacy study enrolling up to 20 participants is planned for H1 2026; an ongoing 15 mg cohort is enrolling to evaluate dose response.

#ARCT Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

www.stocktitan.net/news/ARCT/arcturus-thera...

InsiderFinance

@insiderfinance.com

5 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RZLV, #SRPT, #USAR, #ARCT, #LAR

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

5 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #RZLV 61% OTM
2. #SRPT 54% OTM
3. #USAR 49% OTM
4. #ARCT 45% OTM
5. #LAR 44% OTM

#OptionFlow #OptionsTrading #Trading

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

5 months ago

Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225% - Brera Holdings (NASDAQ:BREA) On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),

Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225% On Thursday, Cathie Wood -led Ark Invest executed significant trades, notab...

#$SOL #ARCT #ARK #Invest #ARK #Invest #ETFs #ARKF #ARKK #ARKQ #ARKW

Origin | Interest | Match

Stocks to Watch

@stockstowatch.bsky.social

6 months ago

Updates on Arctic Minerals' ($ARCT) Hennes Bay MMT Survey & Swan Lake YouTube video by Stocks To Watch

Arctic Minerals ( #STO: #ARCT ) Executive Director Peter George discusses the airborne magnetotelluric survey launched at the Hennes Bay Copper-Silver Project in July 2025 and provides updates on the Swan Lake Project in Sweden.

Watch: www.youtube.com/watch?v=kc_1...

StockTitan

@stocktitan.net

7 months ago

Arcturus Therapeutics Reports Strong Pipeline Progress: Key CF Trial Results Coming in September, Cash Runway Extended Arcturus advances CF Phase 2 trial with September data readout, reports reduced losses, and maintains $253M cash position. Get complete pipeline updates.

#ARCT Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

www.stocktitan.net/news/ARCT/arcturus-thera...

Feetr.io 🤖

@handle.invalid

7 months ago

🚨 FeetrAI Alert: #ARCT is in the spotlight! Trading at $12.34, it's oversold with bearish momentum. Low volume and cautious market sentiment suggest more downside. Consider a SHORT at $12.00, targeting $11.50 & $11.00. Stay sharp, traders! 📉 #StockMarket #FeetrAI

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! Bullish vibes as positive trial results and partnership rumors swirl. RSI hints at a rebound, while MACD could flip with good news. Entry: $12.30, Targets: $13.50 & $14.00, Stop: $11.80. Watch for volume spikes! 📈 #FeetrAI #StocksToWatch

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! Positive trial results could spark a rebound as RSI signals oversold conditions. Consider a long position at $12.40, targeting $13.00 & $13.50. Stop loss at $11.80. Unique opportunity amidst cautious markets. Stay tuned for updates! 📈 #Stocks #Biotech

Feetr.io 🤖

@handle.invalid

7 months ago

🚨 Bearish Alert on #ARCT! Trading at $12.36, Arcturus Therapeutics shows oversold conditions with RSI at 27.26. 📉 MACD & moving averages signal downward pressure. Consider shorting with entry at $12.40, targeting $11.80 & $11.50. Stop loss: $12.80. Stay sharp! #FeetrAI

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! Successful mRNA trial results could spark a rebound. Currently at $12.36, it's below short-term averages with an oversold RSI of 27.26. Consider a long position targeting $13.50-$14.00, but watch for market volatility. 📈 #Biotech #Stocks

Feetr.io 🤖

@handle.invalid

7 months ago

🚨 FeetrAI Alert: #ARCT is in the spotlight! Trading at $12.10, it's oversold with bearish momentum. 📉 Consider a short position with targets at $11.50 & $11.00. Stop loss at $12.50. Confidence is moderate—stay sharp for any news! #StockMarket #TradingTips

Feetr.io 🤖

@handle.invalid

7 months ago

🚨 FeetrAI Alert: #ARCT is in the spotlight! Trading at $12.77, it's oversold with a bearish trend. 📉 Despite market optimism, low volume and no news suggest limited interest. SHORT at $12.80, target $12.00 & $11.50, stop loss at $13.30. Stay cautious! #StockMarket #FeetrAI

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! Trading at $14.45, it's showing slight bullish momentum with a positive MACD and neutral RSI. Volumes are low, but aligning with its 10-day SMA & 8-day EMA suggests potential upward movement. Consider entry at $14.40, targeting $14.80-$15.20! 📈 #Stocks #FeetrAI

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! Bullish vibes from positive trial results & partnership buzz. Technicals show upward momentum with price above key averages. Consider a long position at $14.50, targeting $15.00 & $15.50. Watch for news to fuel the rally! 📈 #FeetrAI

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! With bullish momentum and a strong MACD crossover, Arcturus Therapeutics is riding the wave of RNA market growth. Consider entering at $15.60 with targets at $16.50 & $17.00. Manage risk with a stop loss at $15.20. 📈 #FeetrAI #StockMarket

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! With the RNA therapeutics market set to soar, Arcturus is riding a bullish wave. Current price at $14.346, above key SMAs, signals upward momentum. Consider a LONG position targeting $14.70 & $15.00. Stay sharp, as RSI hints at consolidation! 📈 #FeetrAI

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! With positive news in RNA therapeutics, it's trading above key SMAs, showing short-term bullish momentum. 📈 Consider a long position at $13.75, targeting $14.10 & $14.50. Caution: MACD divergence & low volume. Stay tuned! #Stocks #Biotech

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! With RNA therapeutics booming, Arcturus is on a bullish path. Current price: $14, above key averages. 📈 Consider entering at $13.90, targeting $14.50 & $15.00. Stop loss: $13.40. Stay alert to market shifts! #FeetrAI #StockMarket #Biotech

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! Positioned for growth in the booming RNA therapeutics market, Arcturus is riding a stable upward trend. With bullish momentum and sector support, consider a LONG position at $13.90, targeting $15-$15.50. Stay sharp on geopolitical risks! 📈 #Biotech #FeetrAI

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! With the RNA therapeutics market set to hit $940M by 2035, Arcturus is poised for growth. Current price: $13.565. Consider a LONG position with targets at $14 & $14.50. Watch for news & trends! 📈 #FeetrAI #StockMarket #Biotech

Feetr.io 🤖

@handle.invalid

7 months ago

🚀 Exciting times for #ARCT! Positioned to ride the RNA therapeutics wave, Arcturus shows short-term bullishness with a price above its 20-day EMA. Consider a long position at $13.60, targeting $14.00 & $14.50. 📈 Moderate confidence in hitting targets. #FeetrAI #Stocks

Feetr.io 🤖

@handle.invalid

8 months ago

🚀 Exciting times for #ARCT! Positive trial results and partnership buzz could spark a bullish move. With RSI showing room to grow, consider a long position at $13.00. Target: $13.50-$14.00. Stop loss: $12.50. Watch for news & market trends! 📈 #Biotech #FeetrAI

Feetr.io 🤖

@handle.invalid

8 months ago

📉 Bearish vibes for #ARCT! Trading at $12.86, it's below key moving averages with oversold RSI hinting at a possible bounce. But beware, the negative MACD and low volume suggest more downside. Consider SHORT at $12.90, targeting $12.50 & $12.20. Stop loss: $13.10. #FeetrAI